Parkman Healthcare Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Parkman Healthcare Partners’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.9M	Buy	+364,269	New	+$13.2M	1.53%	26

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parkman Healthcare Partners's INDV Position: Q2 2026 in Review

Parkman Healthcare Partners opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 364,269 shares worth $14.9M. The stake represents 1.53% of the portfolio and ranks #26 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Parkman Healthcare Partners held 364,269 shares of Indivior Pharmaceuticals worth $14.9M as of Q2 2026.
Indivior Pharmaceuticals was a new Parkman Healthcare Partners position in Q2 2026.
Indivior Pharmaceuticals made up 1.53% of Parkman Healthcare Partners's portfolio in Q2 2026, its #26 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.